secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001641172-25-024147
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx Q2 2025 revenue $422k from RenovoCath; DMC recommends continue Phase III trial
--------------------------------------------------------------------------------

- Q2 2025 revenue $422k from commercial RenovoCath sales, up from $0 in Q2 2024.
- Cash $12.3M as of June 30, 2025; net loss $2.9M vs $2.4M YoY.
- Independent DMC recommends continue Phase III TIGeR-PaC trial after second interim analysis; 95 patients randomized, 61 events.
- 13 cancer centers approved as customers (up from 5 in Q1); 4 have used device and placed repeat orders.
- Hired Phil Stocton as Senior Director of Sales; launched PanTheR post-marketing registry study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000164117225024147/0001641172-25-024147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000164117225024147/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-024147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer